Stefano Tamberi

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 93 citations

Medicine, Oncology, Pharmacotherapy +15

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

A. Raimondi, Sara Lonardi, Sabina Murgioni et al. · Annals of Oncology · 2024 · 72 citations · Full text

Medicine, Oncology, Pathology +17

A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.

Stefano Tamberi, Grassi Elisa, Chiara Zingaretti et al. · Journal of Clinical Oncology · 2022 · 32 citations

Medicine, Oncology, Pharmacotherapy +16

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Monica Niger, Federico Nichetti, Lorenzo Fornaro et al. · BMC Cancer · 2024 · 16 citations · Full text

Medicine, Oncology, Surgery +10

723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial

S. Marsoni, Michele Prisciandaro, N. Tarazona Llavero et al. · Annals of Oncology · 2025 · 10 citations

Medicine, Oncology, Surgery +14